Below are our currently enrolling studies for patients with psoriatic arthritis.
Sponsor: Takeda
Protocol Number: TAK-279-PsO-3003
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis.
Detailed Information:
To learn more or see if you qualify: Click Here
Sponsor: UCB Biopharma SRL
Protocol Number: PA0019
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Detailed Information:
To learn more or see if you qualify: Click Here